About us.
What we do.
We believe every patient who could benefit from a cell therapy should have the opportunity to receive one. That's why Cellular Origins exists: to make cell therapies widely accessible through scalable and reliable manufacturing.
We are a team of bioprocessing, automation and robotics engineers, scientists and manufacturing specialists: passionate about removing the manufacturing barriers that prevent cell therapies reaching more patients and working to industrialise cell therapy manufacturing for global demand.
Constellation® is the end-to-end manufacturing solution making our vision a reality. By combining advanced robotics and sterile fluid transfer technology with trusted bioprocessing tools and digital orchestration, Constellation turns manual manufacturing into a coordinated, scalable operation.
Our Origins
Cellular Origins began in 2017 at Cambridge technology consultancy TTP. A team of engineers working across automation, robotics, fluidics, and bioprocess engineering saw the same challenge emerge again and again: the science behind cell therapies was advancing rapidly, but manufacturing remained expensive, manual and difficult to scale.
What started as a technical challenge became a founding mission.
The team set about innovating a solution that could enable the scalable, cost-effective and efficient manufacture of cell therapies and, in January 2023, Cellular Origins was formally launched as a spin-out from TTP. Since then, the business has gone from strength to strength in building its commercial automation platform focused on scalable advanced therapy manufacturing.
In 2025, Cellular Origins completed an oversubscribed USD 40 million (EUR 34.3 million) Series A financing round led by Johnson & Johnson Innovation. Today the company is partnering with organisations around the world to build the manufacturing infrastructure needed to bring advanced therapies to more patients than ever before.
Our investors
At the heart of Cambridge innovation.
Cellular Origins is headquartered in Cambridge, UK, with US operations supporting customers across North America.
Cambridge is one of the world’s leading clusters of science and technology innovation. Our region is home to a globally recognised ecosystem of biotechnology companies, research institutes, startups and technology leaders, all working at the forefront of medical and scientific advancement.
This location gives us access to the world-class engineering, automation and life sciences expertise needed to build the infrastructure for automated cell therapy manufacturing.
Great technology starts with great people.
We might engineer robots, but we much prefer humans. People are at the centre of everything we do and we’re always looking to hire exceptional ones. If you’d like to join our team, check out our open positions.
Our values
Our values permeate our whole organisation; how we engineer, how we collaborate and how we deliver. We communicate honestly, solve complex challenges together and are committed to being a trusted partner for every stage of scale-up.
Integrity
We build trust through transparency, accountability and honesty; being open and truthful about our capabilities, products, and intentions.
Courage
We challenge the status quo, blending proven technologies with bold ideas to make life-saving therapies scalable, accessible, and affordable.
Collaboration
We work side-by-side with customers, partners and each other. Agile methods, shared objectives, and honest feedback create a culture where teamwork drives progress.
Impact
Our work is driven by our mission: make life-saving therapies accessible to patients that need them, through scalable and reliable manufacturing.
Executive team
Edwin Stone, PhD
Chief Executive Officer
PhD in Engineering, University of Cambridge. Having joined TTP in 2004, Edd now has over 20 years' experience developing engineering and automation solutions for the cell and gene therapy industry.
Peter Crossley
Chief Operating Officer
Former engineering and R&D leader at Rolls-Royce, Dyson and Fisher & Paykel. Pete joined TTP in 2006 and brings nearly 30 years of experience in engineering, product development and technology leadership.
Dan Strange, PhD
Chief Technology Officer
M.A./M.Eng. in Engineering and PhD in Tissue Engineering, University of Cambridge. Dan joined TTP in 2013 and has led the development of advanced automation technologies for scalable cell and gene therapy manufacturing.
Jason Jones
Head of Global Business Development
Over 20 years' experience in cell and gene therapy. Former head of Miltenyi Biotec's UK Cell Therapy business and founding Chief Business Officer at Ori Biotech, scaling the company from its first employee to more than 60 staff.
Board of Directors
Edwin Stone
Cellular Origins
Sam Hyde
TTP plc
Asish Xavier
Johnson and Johnson
Innovation
Laurence Garrett
Highland Europe
Luke Rajah
BGF
Ready to explore your
cell therapy scale-up?
We’ll be in touch to arrange a discovery call or in-person visit.